SCB-2019 boosting ChAdOx1-S

1	Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with
2	the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2
3	study
4	
5	Prof. Dr. Sue Ann Costa Clemens, ^{1,2} Dr. Eveline Pipolo Milan, ³ Dr Eduardo Sprinz, ⁴ Dr José
6	Cerbino Neto, ⁵ Dr. Filippo Pacciarini, ⁶ Dr. Ping Li, ⁶ Dr. Hui-Ling Chen, ⁶ Dr. Igor
7	Smolenov, ⁶ Prof. Dr. Andrew Pollard, ¹ Dr. Ralf Clemens ⁷
8	
9	1. Oxford Vaccine Group, Department of Pediatrics, University of Oxford, and the NIHR
10	Oxford Biomedical Research Centre, Oxford, United Kingdom
11	2. Siena University, Siena, Italy
12	3. Centro de Estudos e Pesquisa em Moléstias Infecciosas Ltda. (CEPCLIN), Natal, Brazil
13	4. Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
14	5. D'Or Institute for Research and Education, Rio de Janeiro, Brazil
15	6. Clover Biopharmaceuticals Inc., Cambridge, MA, USA.
16	7. International Vaccine Institute, Seoul, Republic of Korea

SCB-2019 boosting ChAdOx1-S

17 ABSTRACT

18	Background: Ongoing outbreaks of COVID-19 are driven by waning immunity following
19	primary immunizations and emergence of new SARS-CoV-2 variants which escape vaccine-
20	induced neutralizing antibodies. It has been suggested that heterologous boosters could
21	enhance and potentially maintain population immunity.
22	Methods: We assessed immunogenicity and reactogenicity of booster doses of different
23	formulations of alum-adjuvanted SCB-2019 vaccine (9 μ g SCB-2019 with or without CpG-
24	1018 adjuvant, or 30 μ g SCB-2019 with CpG-1018) in Brazilian adults primed with
25	ChAdOx1-S vector vaccine. S-protein antibodies and ACE2-binding inhibition were
26	measured by ELISA on Days 1, 15 and 29. Participants self-reported solicited adverse events
27	and reactions.
28	Results: All SCB-2019 formulations increased S-protein ELISA antibodies and ACE2
29	binding inhibition to a greater extent than ChAdOx1-S. After 30 µg SCB-2019+CpG+alum
30	titers against wild-type S-protein were significantly higher than after ChAdOx1-S on Days 15
31	and 29, as were titers of neutralizing antibodies against wild-type strain and Beta, Gamma,
32	Delta, and Omicron variants. Boosting with SCB-2019 or ChAdOx1-S was well tolerated
33	with no vaccine-related serious or severe adverse events.
34	Conclusions: Boosting ChAdOx1-S-primed adults with SCB-2019 induced higher levels of
35	antibodies against a wild-type strain and SARS-CoV-2 variants than a homologous
36	ChAdOx1-S booster, highest responses being with the 30 μ g SCB-2019+CpG+alum
37	formulation.
38	KEYWORDS
39	COVID-19; vaccine; booster; heterologous; homologous, SCB-2019; ChAdOx1-S

40 Registered on ClinicalTrials.gov, NCT 05087368

SCB-2019 boosting ChAdOx1-S

41	Conflict of Interest statement
42	FP, PL, IE, H-LC, and IS are all full-time employees of the study sponsor. SACC and RC are
43	scientific advisors to the study sponsor. EPM, ES, JCN and AP declare they have no conflicts
44	to declare. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts
45	of Interest and conflicts that the editor considers relevant to the content of the manuscript
46	have been disclosed.
47	
48	Funding statement
49	The study was sponsored by Clover Biopharmaceuticals Inc. and was supported by grant
50	from Bill & Melinda Gates Foundation (BMGF), No. INV-030336.
51	
52	Corresponding Author
53	Dr. Ralf Clemens,
54	International Vaccine Institute,
55	SNU Research Park,
56	1 Gwanak-ro,
57	Gwanak-gu,
58	Seoul,
59	08826 Korea
60	E-mail: clemens.ralf@outlook.com
61	

SCB-2019 boosting ChAdOx1-S

62 INTRODUCTION

63	The COVID-19 pandemic has been ongoing for two years, during which time large
64	proportions of high-income country populations have achieved vaccine-induced immunity
65	following national immunization campaigns [1]. However, new variants of the wild-type
66	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from Wuhan have continued
67	to emerge each displaying new mutations of the Spike protein (S-protein) [2]. As the S-
68	protein is the main antigenic target of most of the authorized vaccines, the accumulating
69	mutations have resulted in these new variants becoming successively less susceptible to the
70	neutralizing immunity induced by the first immunization campaigns [3–7]. This has resulted
71	in new waves of pandemic COVID-19 outbreaks, most notably associated with the Beta
72	(B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants [8]. The
73	efficacy of authorized vaccines against infection has been seen to decrease with each new
74	variant, both due to waning immunity following immunization and the changes in the
75	antigenic target, while protection against severe disease is largely preserved.
76	This has led to the implementation of further immunization campaigns with booster doses of
77	vaccines to broaden the immune response. Early indications are that heterologous boosters
78	are mostly more effective than homologous boosters [9–11]. Most data on such immunity has
79	been obtained with the mRNA vaccines which were the first to be authorized for use in
80	immunization campaigns and have been widely used in high-income countries. However,
81	many low- and middle-income countries are still in the phase of implementing full primary
82	immunization of their populations, with widespread use of viral vector (e.g., ChAdOx1-S1;
83	AstraZeneca, United Kingdom) or inactivated (e.g., CoronaVac; Sinovac Biotech, China)
84	vaccines. Clover Biopharmaceuticals has developed a recombinant SARS-CoV-2 S-protein
85	vaccine (S-Trimer), SCB-2019, that has been stabilized in the native pre-fusion trimeric
86	conformation using the company's proprietary Trimer-Tag [©] technology and adjuvanted with

SCB-2019 boosting ChAdOx1-S

87	the toll-like receptor 9 (TLR 9) agonist CpG-1018 and alum. The SPECTRA phase 2/3
88	efficacy trial demonstrated that two 30 μg doses of SCB-2019 had 67.2% (95.72% CI: 54.3–
89	76.8) efficacy against any COVID-19, and specific efficacies (with 95% CI) of 78.7% (57.3-
90	90.4), 91.8% (44.9–99.8) and 58.6% (13.3–81.5) against Delta, Gamma and Mu variants,
91	respectively [12]. The present study was conducted to investigate use of SCB-2019 in
92	heterologous booster regimens compared with homologous boosters in individuals who have
93	received a two-dose primary vaccination series of the adenovirus-vector vaccine, ChAdOx1-
94	S, which was authorized in Brazil. We assessed safety and immunogenicity of different
95	formulations of SCB-2019; low dose (9 μ g) SCB-2019 and alum, with and without the CpG-
96	1018 adjuvant to investigate possible dose-sparing, and the standard 30 μ g dose formulated
97	with CpG-1018 and alum used in the SPECTRA efficacy trial. These were given as a
98	heterologous booster in persons primed with two doses of ChAdOx1-S and responses
99	compared with a dose of ChAdOx1-S given as a homologous booster.
99 100	compared with a dose of ChAdOx1-S given as a homologous booster. METHODS
99 100 101	 compared with a dose of ChAdOx1-S given as a homologous booster. METHODS This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three
99 100 101 102	 compared with a dose of ChAdOx1-S given as a homologous booster. METHODS This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three sites in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and
99 100 101 102 103	compared with a dose of ChAdOx1-S given as a homologous booster. METHODS This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three sites in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal. The study
99 100 101 102 103 104	compared with a dose of ChAdOx1-S given as a homologous booster. METHODS This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three sites in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal. The study protocol was approved by each hospital's Ethical Review committee and conducted
99 100 101 102 103 104 105	compared with a dose of ChAdOx1-S given as a homologous booster. METHODS This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three istes in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal. The study protocol was approved by each hospital's Ethical Review committee and conducted according to the Declaration of Helsinki and Council for International Organizations of
 99 100 101 102 103 104 105 106 	compared with a dose of ChAdOx1-S given as a homologous booster. METHODS This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three istes in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal. The study protocol was approved by each hospital's Ethical Review committee and conducted according to the Declaration of Helsinki and Council for International Organizations of Medical Sciences International ethical guidelines and ICH GCP guidelines. The protocol was
 99 100 101 102 103 104 105 106 107 	compared with a dose of ChAdOx1-S given as a homologous booster. METHODS This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three istes in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal. The study protocol was approved by each hospital's Ethical Review committee and conducted according to the Declaration of Helsinki and Council for International Organizations of Medical Sciences International ethical guidelines and ICH GCP guidelines. The protocol was protocol vas approved by each not protocol was and ICH GCP guidelines and protocol was approved by ethical ethical guidelines and ICH GCP guidelines. The protocol was
 99 100 101 102 103 104 105 106 107 108 	compared with a dose of ChAdOx1-S given as a homologous booster. METHODS This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three istes in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal. The study protocol was approved by each hospital's Ethical Review committee and conducted iccording to the Declaration of Helsinki and Council for International Organizations of Medical Sciences International ethical guidelines and ICH GCP guidelines. The protocol was registered on ClinicalTrials.gov, registration number NCT 05087368. Participants supplied written informed consent at enrolment. The objective reported here was to select the optimal
 99 100 101 102 103 104 105 106 107 108 109 	compared with a dose of ChAdOx1-S given as a homologous booster. METHODS This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three istes in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal. The study protocol was approved by each hospital's Ethical Review committee and conducted according to the Declaration of Helsinki and Council for International Organizations of Medical Sciences International ethical guidelines and ICH GCP guidelines. The protocol was registered on ClinicalTrials.gov, registration number NCT 05087368. Participants supplied written informed consent at enrolment. The objective reported here was to select the optimal

immunogenicity, and potential impact on supply of the chosen formulation, i.e. dose-sparing.

SCB-2019 boosting ChAdOx1-S

112 Participants

113	Eligible participants were male or female adults, ≥ 18 years of age who had previously
114	received two doses of ChAdOx1-S1-S vaccine 6 months (\pm 4 weeks) before enrolment and
115	were willing and able to comply with study requirements, including all scheduled visits,
116	vaccinations, laboratory tests, and other study procedures. Inclusion criteria included being
117	healthy or having a pre-existing but stable medical condition at the screening examination,
118	the main exclusion criterion being any previous laboratory-confirmed SARS-CoV-2
119	infection.
120	Vaccine
121	The investigational SCB-2019 vaccine was supplied in a 1.0·mL pre-filled syringe containing
122	720 µg SCB-2019. Adjuvants were CpG-1018 (Dynavax Technologies) presented in a 2.0 ml
123	vial containing 12 mg/mL of a 22-mer phosphorothioate oligodeoxynucleotide in Tris
124	buffered saline (24 mg per vial), and aluminium hydroxide (Alhydrogel®, Croda Health
125	Care) supplied in vials of 10 mg/mL. The final vaccine formulations per dose contained
126	either 30 μg SCB-2019 with 1.5 mg CpG-1018 and 0.75 mg alum in a 0.5 mL volume, as
127	used in the reported efficacy trial [12], 9 μ g SCB-2019 with 0.225 mg alum in a 0.15 mL
128	dose, or 9 μg SCB-2019 with 0.45 mg CpG-1018 and 0.225 mg alum in a 0.15 mL volume.
129	The comparator vaccine (ChAdOx1-S1-S) was Fiocruz COVID-19 vaccine (Rio de Janeiro,
130	Brazil) containing a Chimpanzee Adenovirus (ChadOx1) encoding the SARS-CoV-2 Spike
131	glycoprotein, with not less than 2.5×10^8 infectious units (Inf.U) in each 0.5 ml dose. These
132	vaccine formulations were prepared on the day of use by trained unblinded vaccine
133	administrators who administered them by intramuscular injection in the upper deltoid of the
134	non-dominant arm. For accurate administration of the 0.15 mL volume 1 mL tuberculin
135	syringes (Precisionglide, Becton Dickenson) were used. These vaccine administrators played

SCB-2019 boosting ChAdOx1-S

136 no further part in the study and all other study staff and the investigators and participants

137 were masked to which vaccine had been given.

138 Procedures

139 At enrolment participants were randomly allocated 1:1:1:1 using a block size of 8 to four

140 equal groups to receive a third dose of ChAdOx1-S1 or a dose of one of the three

141 formulations of SCB-2019. At their first study visit on Day 1, after providing their baseline

- blood sample, participants received their assigned vaccination and were monitored for 30
- 143 minutes for any immediate reactions. Using diary cards they then recorded for 7 days the

144 occurrence of solicited local reactions (pain, erythema and swelling at the injection site) and

145 systemic adverse events (fatigue, headache, myalgia, arthralgia, loss of appetite, nausea,

146 chills, fever [axillary temperature $\geq 38^{\circ}$ C]) daily, together with any unsolicited adverse

147 events, serious adverse events (SAE) or medically attended adverse events (MAAE)

148 occurring up to the third study visit on Day 29. At this study visit the investigator assessed

any reported AE as mild (no interference with daily activities), moderate (interferes with

- daily activities) or severe (prevents daily activity) and the relationship to the study
- 151 procedures.

152 Immunogenicity

153 Serum samples obtained on Day 1 (before vaccination) and at the second (Day 15) and third

- 154 (Day 29) visits were used to assess immune responses. The primary endpoint was the
- response assessed by ELISA as IgG antibodies against SCB-2019 S-protein on Days 15 [12].
- 156 Inhibition of binding of S-protein to the human angiotensin converting enzyme 2 (ACE2) was
- 157 measured using a competitive ELISA with SCB-2019. Additional exploratory analyses
- included virus neutralizing activity (VNA) titers measured on Days 1, 15 and 29 in a

SCB-2019 boosting ChAdOx1-S

159	microneutralization assa	y (MN ₅₀)) against the	prototype Wuhan	strain and the	Beta (B.1.351).	

160 Delta (B.1.617.2), Gamma (P.1) and Omicron (B.1.1.529) variants of SARS-CoV-2.

161 *Statistics*

162	There was no formal hypothesis tested in this first stage of the study, all results being
163	presented and analyzed descriptively. The sample size was considered adequate for the
164	purposes of down-selection of formulation. The primary immunogenicity endpoint was
165	ELISA antibody titers against SCB-2019 S-protein expressed as geometric mean titers
166	(GMT), geometric mean-fold rise in titers over baseline (GMFR) and seroconversion rates
167	(SCR) on Days 15 and 29 in all participants who received the correct vaccination and had no
168	major protocol deviation reported or suffered a COVID-19 infection prior to blood draw.
169	Seroconversion was defined as a \geq 4-fold increase in post-vaccination titer in those with a
170	baseline titer above the lower limit of quantitation (LLOQ), or a post-vaccination titer \geq 4-
171	fold the LLOQ in those with no detectable activity at baseline. Comparisons between groups
172	were made by ANCOVA model with vaccine group as a fixed variable, baseline antibody
173	result and site as covariates. Immunogenicity results against the different SARS-CoV-2
174	variants are also expressed as GMTs, GMFR and SCR for group and variant. GMTs of
175	neutralizing antibodies against prototype strain ELISA GMTs against SCB-2019 S-protein
176	are presented in IU/mL, GMTs of neutralizing antibodies against variants and ACE2 are
177	expressed in reciprocal units. Safety data is presented descriptively as proportions of groups
178	(percentage) reporting any solicited reaction or adverse event or unsolicited adverse events.

179

180 **RESULTS**

181 Recruitment began on November 26, 2021 and the last volunteer was enrolled on March 7,

182 2022. During this period there was a major outbreak of Omicron infections. Of 144

SCB-2019 boosting ChAdOx1-S

183	volunteers screened a total of 120 volunteers were enrolled and randomized to the four study
184	groups (Figure 1). Only two enrolled participants did not complete through visit 3; one was
185	lost to follow-up from Group 1 after visit 1 and the second was lost to follow-up from Group
186	2 after visit 2. All of the remaining 118 randomized participants completed through visit 3,
187	except for one from Group 1 who did not provide blood for immunology assessment.
188	Demographics in the four study groups were comparable (Table 1). Over the course of the
189	study there were 30 suspected cases of COVID-19 in the study population, 26 of which were
190	confirmed by RT-PCR and 2 by rapid antigen test (RAT). These occurred in all four study
191	groups with onset from 8 to 77 days after vaccination (Table 1). Three cases had onset before
192	Day 15, and a further ten before Day 29, the remaining 17 having onset after visit 3. The
193	participants with confirmed COVID-19 infection before the second blood sample were
194	excluded from the relevant immunogenicity analyses.

195 *Immunogenicity*

196 Vaccination in any of the four study groups resulted in increases in titers of binding

197 antibodies against SCB-2019 and inhibition of S-protein binding to ACE2 which were

198 notably higher in Groups 1–3 which received the heterologous SCB-2019 formulation than

199 Group 4 after a homologous ChAdOx1-S booster (Figure 2). Following the SCB-2019

200 boosters these increases were apparently dose dependent; in Groups 1 and 2 which received 9

μg SCB-2019 the respective GMFR from Day 1 were 9 and 11 at Day 15 and 8 and 9 at Day

202 29, while in Group 3 the GMFR were 18 and 16 at Days 15 and 29 suggesting the 30 µg

203 SCB-2019 dose was more effective in inducing a booster response (Figure 2A). Notably, all

three SCB-2019 groups elicited significantly higher GMFR than the four-fold increase

elicited by the homologous ChAdOx1-S booster vaccination at Day 15. The response

206 increased further in Group 4 at Day 29, but the significant difference persisted between

207 Groups 3 and 4.

SCB-2019 boosting ChAdOx1-S

208	A similar profile was observed when measuring ACE2 binding (Figure 2B) with higher fold-
209	increases in all groups at Days 15 and 29 than with the S-protein assay, which were still dose
210	dependent in the SCB-2019 groups. This immune response was significantly higher in
211	Groups 2 and 3 than in Group 4, the ChAdOx1-S-boosted group and this significant
212	difference persisted at Day 29 when al four groups displayed higher titers with GMFR
213	ranging from 23 to 34 in the three SCB-2019 groups compared with a GMFR of 12 in the
214	ChAdOx1-S group.
215	When assessed for neutralizing activity against the protype strain and the different SARS-
216	CoV-2 variants at Day 15 these differences between different doses of SCB-2019 and
217	between SCB-2019 and ChAdOx1-S were still evident (Figure 3). All groups displayed
218	neutralizing activity against all five variants at baseline, the highest responses being against
219	the prototype Wuhan virus and the lowest against the most recent variant, Omicron
220	(B.1.1529). Two weeks after vaccination there were marked increases against all five variants
221	in all four groups, with significantly higher increases after heterologous SCB-2019 doses in
222	Groups 2 and 3 than the homologous ChAdOx1-S dose in Group 4. Overall, the biggest
223	increases in SCB-2019 groups were against prototype virus with GMFR ranging from 10 to
224	15 (Table 2) and Delta variant (GMFR 9 to 17), and lowest against Omicron with GMFR
225	ranging from 4 to 6. The GMFR in Group 4, after a booster ChAdOx1-S vaccination, ranged
226	from 2 to 5 for the different variants. When the GMTs of each group vs Group 4 were
227	compared the responses in Groups 2 and 3 were significantly higher than Group 4 against all
228	variants (Figure 3). Similarly, seroconversion rates for each variant were highest with the 30
229	μ g SCB-2019 formulation, with a notably higher response against Omicron than the
230	homologous ChAdOx1-S booster (Table 2). Interestingly, the significant differences between
231	Groups 2 and 4, the low-dose fully adjuvanted SCB-2019 and ChAdOx1-S, did into persist to

SCB-2019 boosting ChAdOx1-S

Day 29 except for the Gamma variant. This was due in equal parts to waning titers in Group 2and increasing titers in Group 4.

234 Safety

235 Overall, all four vaccine formulations were well tolerated, with no vaccine-related serious or

severe adverse events, no withdrawals due to an AE and no deaths (Table 3). The only

237 reported SAE was a leg fracture which was not related to the study procedures. One female

238 participant with a history of hypertension and prior COVID-19 infection reported a mild

allergic reaction 13 days after vaccination which resolved but was repeated 5 days later. The

240 investigator considered the first occurrence to be related to the study vaccine, but not the

second.

242 There were no clinically meaningful differences in rates of solicited local reactions between

243 the groups. Rates were highest in Group 2 (41%) and Group 3 (47%), after 9 μ g and 30 μ g

SCB-2019 with CpG and alum, respectively. The rate was lower (29%) in Group 1 who

received 9 µg SCB-2019 with alum alone. After the homologous ChAdOx1-S vaccination

246 33% of Group 4 reported a local reaction. Local reactions in all four groups mainly consisted

of mild pain at the injection site with a few cases described as moderate but none as severe

248 (Figure 4). Solicited systemic AEs were most frequently reported after the ChAdOx1-S in

Group 4 (63%), with lower rates (39% to 43%) in the SCB-2019 groups. The most frequent

solicited systemic AEs were headache, fatigue and myalgia (Figure 4), which were mainly

251 mild and transient, with no severe cases reported. As with local reactions there were no

252 clinically meaningful differences in systemic AEs between groups. There were no AESIs or

severe unsolicited AEs reported over the course of the study.

As noted, there were 30 cases of COVID-19 reported, including 13 from Day 1 to Day 29

when immunogenicity was assessed. Of these 25 were considered to be mild and 5 as

SCB-2019 boosting ChAdOx1-S

256 moderate in severity; no cases were described as severe or had associated pneumonia or

- 257 required hospitalization.
- 258

259 **DISCUSSION**

260	This study is the first investigation of boosting immune responses with Clover's recombinant
261	SARS-CoV-2 S-trimer fusion protein vaccine (SCB-2019) as a heterologous vaccine to the
262	primary vaccine. This study also investigated the use of a lower dose of SCB-2019, with and
263	without the CpG-1018 adjuvant, to allow for dose-sparing. The data show that the best
264	booster response in participants primed with two doses of the adenoviral vector vaccine,
265	ChAdOx1-S, was provided by the standard formulation containing 30 μ g SCB-2019 with the
266	toll-like receptor 9 agonist CpG-1018 and alum. This formulation demonstrated 67.2%
267	efficacy against COVID-19 of any severity in the SPECTRA study and 100% efficacy
268	against severe disease [12]. As a heterologous booster it was not associated with any safety
269	concerns and had acceptable reactogenicity, comparable to that observed in the SPECTRA
270	study following primary immunizations [12]. The 30 μ g SCB-2019 dose elicited significantly
271	higher immunity against the two key antigenic targets, measured as antibodies against SARS-
272	CoV-2 S-protein and inhibition of the binding of S-protein to the ACE2 receptor, than the
273	homologous ChAdOx1-S vaccine. Further, neutralizing antibody responses against four of
274	the major SARS-CoV-2 variants were significantly higher than with the homologous
275	ChAdOx1-S vaccine. These observations are important as ChAdOx1-S has been shown to be
276	highly protective against severe disease and death since its global roll out.
277	One exception was the level of neutralizing activity against the Omicron variant; although
278	significantly lower 15 days after homologous boosting than with heterologous with SCB-
279	2019+CpG+alum formulations, titers against Omicron were comparable at Day 29. This was

SCB-2019 boosting ChAdOx1-S

280	partly due to a continuing increase in these titers in the ChAdOx1-S group while they waned
281	slightly in the SCB-2019 groups. The question of whether this indicates a difference in the
282	kinetics of the response to the homologous booster requires further investigation. It has
283	previously been observed that the immune response to a heterologous second vaccination
284	using mRNA vaccines after a primary dose of ChAdOx1-S is more rapid than the
285	homologous vaccination, but we are unaware of similar observations with a protein or
286	inactivated vaccine [13].

287 The COVID-19 pandemic has decreased in severity but has endured in numbers of infections 288 with the appearance of new variants which despite appearing to be less sensitive to vaccine-289 induced immunity, are also leading to less severe forms of disease with fewer hospitalizations 290 and deaths [14]. However, SARS-CoV-2 remains a threat to global health, and the experience 291 of a series of novel variants emerging and rapidly predominating in circulation highlights the 292 potential for future outbreaks. In a situation analogous to influenza, in a population that now 293 has immune experience due to infection or vaccination, future variants may lead to seasonal 294 outbreaks. For that reason, it is essential that high levels of immunity are maintained in global 295 populations to ensure there are no more explosive outbreaks of serious illness such as those 296 the world has recently experienced [15].

297 Many countries have already achieved high levels of immunity, notably those high-income 298 countries that were able to initiate mass immunization campaigns with the first vaccines to be 299 authorized, mainly the mRNA and vector vaccines targeting the S-protein of the prototype 300 virus [1]. Middle- and low-income countries are now playing catch-up, typically using less 301 expensive and more easily managed inactivated vaccines. However, the steady emergence of 302 a series of novel variants, the majority of which have changes in the main antigenic target, 303 the S-protein, has seen a decline in the extent of protective immunity afforded by the initial 304 vaccines [3-8]. The combination of waning antibodies and lower immunity against the novel

SCB-2019 boosting ChAdOx1-S

305	variant has caused resurgence of COVID-19 outbreaks around the world, which may be
306	countered by use of booster vaccinations [16]. Unfortunately, boosters only provide a
307	temporary solution as waning immunity and emergence of new escape variants means that
308	the added protection will be short-lived.
309	Evidence so far suggests that in most cases boosting with a heterologous vaccine is more
310	effective than homologous boosters [17–19] which this report appears to confirm with the
311	heterologous SCB-2019 booster eliciting higher immunity than a dose of the heterologous
312	ChAdOx1-S vaccine. In view of the global need for more COVID-19 vaccines we also
313	assessed the effect of a reduced dose of SCB-2019 to allow dose-sparing as well as omitting
314	the CpG-1018 adjuvant, which may also be dose-limiting. Our results suggest that both
315	formulations of SCB-2019 with CpG and alum containing 9 μ g or 30 μ g doses, provide an
316	important boost in immunity with no evidence of increased reactogenicity.
317	This is a small study with several limitations as a consequence, but the trends are
318	confirmation of other observations. Several studies have shown that heterologous booster
319	vaccination can heighten and broaden the immune response compared with homologous
320	booster doses [17–19]. We restricted this study to one priming vaccine, ChAdOx1-S, but
321	results need to be confirmed with other vaccines, particularly mRNA and inactivated
322	vaccines. We only assessed the immune responses out to four weeks after the booster
323	vaccination, and persistence of any improved immune responses following the heterologous
324	and homologous boosters will have to be assessed. Finally, we did not assess the efficacy of
325	the booster immunization; although there were several cases of COVID-19 reported in this
326	small study population it was not designed to include an efficacy assessment which would
327	also require a placebo group. Notably, none of these cases were severe and there were no
328	hospitalizations due to COVID-19.

SCB-2019 boosting ChAdOx1-S

- 329 In conclusion, the formulation of 30 µg SCB-2019 adjuvanted with CpG-1018 and alum is
- safe and well tolerated and as a heterologous booster vaccine in those previously primed with
- 331 ChAdOx1-S and is immunologically more effective than that same vaccine given as a
- 332 homologous booster.

SCB-2019 boosting ChAdOx1-S

334 ACKNOWLEDGEMENTS

335	The authors wish to thank all participants and our co-investigators Drs. Tannyth Gomes dos
336	Santos, Karla Cristina Marques Afonso Ferreira de Souza, and Deyvison Soares da Costa at
337	CEPCLIN, Natal; Drs. Thaina Garbino, Larisse Longo, and Caroline Portela at Hospital de
338	Clínicas de Porto Alegre, Porto Alegre; and Drs. Bruno Pereira Stuchi, Luciana Gomes Pedro
339	Brandão, and Marcellus Dias da Costa at Hospital Glória D'or, Rio de Janeiro for their
340	invaluable contribution to this study. We are grateful to all the personnel at Vismederi SRL
341	(Siena, Italy) for their expertise in performing the immunogenicity assays, to the staff at
342	Smerud Medical Research (Oslo, Norway) for data management, and to Intrials (São Paulo,
343	Brazil) for their conduct of the study. The ChAdOx1-S vaccine used in the study was
344	generously provided by the Ministry of Health (Brasília, Brazil). The authors are grateful to
345	Keith Veitch (keithveitch communications, Amsterdam, the Netherlands) for assistance with
346	preparation and editorial management of the manuscript.

SCB-2019 boosting ChAdOx1-S

347 **REFERENCES**

348 349	1.	Our World in Data. Coronavirus (COVID-19) vaccinations. Apr 24, 2021. https://ourworldindata.org/covid-vaccinations Accessed on April 24, 2022.
350 2 351	2.	Candido KL, Eich CR, de Fariña LO, et al. Spike protein of SARS-CoV-2 variants: a brief review and practical implications. Braz J Microbiol 2022 Apr 9;1–25.
352 3 353 354	3.	Murano K, Guo Y, Siomi H. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. Biochem Soc Trans 2021; 49:2879-90.
355 4 356	4.	Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021; 384:1885–98.
357 5 358	5.	V. Shinde S, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021; 384:1899–1909.
359 (360 361	5.	Noor R, Shareen S, Billah M. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants. Bull Natl Res Cent 2022; 46:96.
362 7 363 364	7.	Keegan LT, Truelove S, Lessler J. Analysis of vaccine effectiveness against COVID-19 and the emergence of Delta and other Variants of Concern in Utah. JAMA Network Open 2021; 4:e2140906.
365 8 366 367	8.	Alcantara LCJ, Nogueira E, Shuab G, et al. SARS-CoV-2 epidemic in Brazil: how variants displacement have driven distinct epidemic waves. Virus Res 2022; 198785. Online ahead of print DOI: 10.1016/j.virusres.2022.198785.
368 9 369	9.	Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature 2021; 600:701–6.
370 371 372	10.	Groβ R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine 2022; 75:103761.
 373 374 375 376 	11.	Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health 2022 Published Online April 23, 2022 https://doi.org/10.1016/S2214-109X(22)00112-7

SCB-2019 boosting ChAdOx1-S

377 378 379	12.	Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2022; 399:461–72.
380 381	13.	Markewitz R, Juhl D, Paiuli D, et al. Kinetics of the antibody response to boostering with three different vaccines against SARS-CoV-2. Front Immunol 2022; 13:811020.
382 383 384	14.	Wrenn JO, Pakal SB, Vestal G, et al. COVID-19 severity from Omicron and Delta SARS-CoV-2 variants. Influenza Other Respir Viruses 2022 Online ahead of print Apr 13. doi: 10.1111/irv.12982.
385 386	15.	Soraci L, Lattanzio F, Soraci G, et al. COVID-19 vaccines: current and future perspectives. Vaccines (Basel) 2022; 10:608.
387 388 389	16.	Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis 2022 Online ahead of print Apr 8;S1473-3099(22)00146-3.
390 391 392 393	17.	Hayashi JY, Simizo A, Miyamoto JG, et al. Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2. J Infect Dis 2022; Online ahead of print Feb 27;S0163-4453(22)00115-3. doi: 10.1016/j.jinf.2022.02.026.
394 395 396 397	18.	Cohen G, Jungsomsri P, Sangwongwanich J, et al. Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines. Hum Vaccin Immunother 2022 Online ahead of print Mar 24;1- 7. doi: 10.1080/21645515.2022.2052525.
398 399	19.	Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix? Lancet Infect Dis 2022; 22:P438–40.

	Group 1	Group 2	Group 3	Group 4
Charactoristics	9 µg SCB-2019	9 µg SCB-2019	30 µg SCB-2019	
	+ alum	+ CpG + alum	+ CpG + alum	CHAUOXI-S
	N = 30	N = 29	N = 32	N = 29
Sex, n (%)				
Male	15 (50)	12 (41)	12 (38)	13 (45)
Female	15 (50)	17 (59)	20 (63)	16 (55)
Mean age ± SD, yr	43.4 ± 14.4	40.0 ± 13.6	39.8 ± 12.1	36.8 ± 12.7
(Range)	(20, 66)	(21, 63)	(22, 63)	(21, 64)
Race, n (%)				
American Indian/Alaskan native	0 (0)	0 (0)	0 (0)	1 (3)
Black or African American	1 (3)	4 (14)	2 (6)	4 (14)
White	25 (83)	22 (76)	25 (78)	21 (72)
Other	2 (7)	3 (10)	4 (13)	2 (7)
Unknown/not reported	2 (7)	0 (0)	1 (3)	1 (3)
Ethnic group, n (%)				
Hispanic or Latino	21 (70)	26 (90)	20 (63)	19 (66)
Not Hispanic or Latino	2 (7)	1 (3)	9 (28)	4 (14)
Unknown/not reported	7 (23)	2 (7)	3 (9)	6 (21)
Mean body mass index ± SD, kg/m ²	28.5 (4.9)	28.9 (6.4)	27.5 (5.6)	27.8 (6.5)
(Range)	(19.8, 37.9)	(17.3, 42.3)	(18.3, 46.3)	(20.0, 44.5)
Risk of severe COVID-19ª, n (%)				
Low	18 (60)	18 (62)	24 (75)	21 (72)
High	12 (40)	11 (38)	8 (25)	8 (28)
COVID-19 infections during the study, n (%)	8 (27)	7 (24)	9 (28)	6 (21)
Time from vaccination, Mean ± SD, days	32.4 ± 12.0	44.3 ± 14.6	24.0 ± 8.2	43.2 ± 23.2
(Range)	(8, 47)	(32, 67)	(13, 37)	(8, 47)

a. Risk due to presence of known co-morbidities

Table 2: Geometric mean-fold rises (GMFR) at Days 15 and Day 29 from Day 0, and seroconversionrates (SCR) on Days 15 and 29 for antibodies against the prototype SARS-CoV-2 and fourvariants measured by microneutralization test (MNT₅₀).

	-	Group 1	Group 2	Group 3	Group 4
Dav	Booster vaccine	9 µg SCIB-2019	9 µg SCIB-2019	30 µg SCIB-2019	ChAdOx1-S
Day					
	n	24	25	25	25
15		10 (6, 17)	17 (10, 30)	15 (0, 27)	23 A (2 7)
15	SMFR (93 % CI)	10(0-17)	949 ((64,06)	949 ((64, 06)	4(3-7)
	SCR (95% CI)	1976 (50-95)	04% (04-90)	64 % (04–90)	40% (20-09)
20		22 E (2, 7)	24 C (4, 44)	19 43 (7, 00)	23 2 (2, 6)
29	GIVIER (95% CI)	5 (3-7)	0 (4-11) 719 ((40, 97)	13(7-23)	3 (2-6)
	SCR (95% CI)	04% (41–83)	71% (49-87)	84% (60-97)	39% (20-62)
		BI		05	05
45		24 7 (5,40)	25	25 44 (7, 00)	25 F (0, 7)
15		7 (5-12)	10 (6-18)	11(7-20)	5(3-7)
	SCR (95% CI)	75% (53–90)	76% (55–91)	80% (59–93)	52% (31-72)
		22	24	19	23
29	GMFR (95% CI)	6 (4-9)	10 (6–17)	12 (7–20)	6 (3–12)
	SCR (95% CI)	68% (45–86)	83% (63–95)	90% (67–99)	61% (39–80)
		GA	MMA variant		
	n	24	25	25	25
15	GMFR (95% CI)	11 (7–18)	14 (8–25)	15 (8–28)	5 (3–9)
	SCR (95% CI)	79% (58–93)	84% (64–96)	80% (59–93)	56% (35–76)
	n	22	24	19	23
29	GMFR (95% CI)	6 (4–9)	8 (5–13)	13 (7–25)	4 (2–7)
	SCR (95% CI)	68% (45–86)	75% (53–90)	79% (54–94)	44% (23–66)
	1	DE	LTA variant	1	
	n	24	25	25	25
15	GMFR (95% CI)	9 (5–14)	11 (6–19)	17 (10–27)	5 (3–8)
	SCR (95% CI)	75% (53–90)	76% (55–91)	88% (69–98)	56% (35–76)
	n	22	24	19	23
29	GMFR (95% CI)	6 (4–11)	7 (4–13)	16 (10–27)	5 (2–9)
	SCR (95% CI)	68% (45–86)	75% (53–90)	90% (67–99)	48% (27–69)
		OMI	CRON variant		
	n	24	25	25	25
15	GMFR (95% CI)	4 (2–6)	4 (3–7)	6 (4–10)	2 (1–4)
	SCR (95% CI)	50% (29–71)	64% (43–82)	68% (47–85)	20% (6.8–41)
	n	22	24	19	23
29	GMFR (95% CI)	4 (2–6)	4 (2–6)	5 (3–8)	5 (2–9)
	SCR (95% CI)	55% (32–76)	58% (37–78)	58% (34–80)	52% (31–73)

Seroconversion defined as a four-fold increase in titer over baseline at Day 1 or from LLoQ if Day 1 titer was < LLoQ.

GMFR = Geometric mean fold rise from Day 1 at Day 15 or Day 29

	Group 1	Group 2	Group 3	Group 4
Vaccine	9 µg SCB-2019 + alum	9 µg SCB-2019 + CpG + alum	30 µg SCB-2019 + CpG + alum	ChAdOx1-S
	N = 30	N = 29	N = 32	N = 29
Any solicited local AE	8/28 (29%)	11/27 (41%)	14/30 (47%)	9/27 (33%)
Mild	7/28 (25%)	11/27 (41%)	13/30 (43%)	8/27 (30%)
Moderate	1/28 (4%)	0/27 (0%)	1/30 (3%)	1/27 (4%)
Any solicited systemic AE	11/28 (39%)	14/27 (52%)	13/30 (43%)	17/27 (63%)
Mild	9/28 (32%)	10/27 (37%)	7/30 (23%)	13/27 (48%)
Moderate	2/28 (7%)	4/27 (15%)	6/30 (20%)	4/27 (15%)
Any unsolicited AE				
Any SOC	10 (33%)	19 (66%)	16 (50%)	11 (38%)
Grade 3 related	0	0	0	0
Grade 3 not related	0	1	0	0
Serious adverse events (SAE)				
Any	0	1 (3%)*	0	0
Related	0	0	0	0
Medically attended AE (MAAE)	5 (17%)	7 (24%)	9 (28%)	6 (21%)
AE of special interest (AESI), AE leading to early withdrawal, or death	0	0	0	0

* One participant suffered a leg fracture which was considered to be unrelated to the study.

SCB-2019 boosting ChAdOx1-S

Figure legends

- **Figure 1.** Study flow chart showing the disposition of the participants to each of the four groups.
- **Figure 2.** Booster vaccination responses shown as geometric mean titers (95% CI) of ELISA antibodies against SCB-2019 (panel **A**) and ACE2 (panel **B**) at Days 15 and 29 after vaccination. Geometric mean-fold rises (GMFR) from Day 1 (95% CI) are shown with ANCOVA *p* values of differences between Groups 1-3 (SCB-2019) and Group 4 (ChAdOx1-S): * *p* <0.05; ** p < 0.01, *** p < 0.001). Numbers in columns are n values per group.
- Figure 3. Booster vaccination responses shown as geometric mean neutralizing titers (with 95% CI) against the indicated SARS-CoV-2 variants 15 days after vaccination. Differences in GMTs of Groups 1-3 vs. Group 4 at Day 15 were tested by ANCOVA; * p < 0.05; ** p < 0.01; *** p < 0.001.</p>
- **Figure 4.** Solicited local reactions and systemic adverse events occurring within 7 days of vaccination by severity reported as percentages of each group.





SCB-2019 boosting ChAdOx1-S

Figure 2.





25

SCB-2019 boosting ChAdOx1-S

SCB-2019 boosting ChAdOx1-S

Figure 4.

